Share on LinkedInShare on LinkedIn

ARTICLE · 12 JANUARY 2023

Life Science M&A: Investment Lifecycle Optimization

Dealmaking in the biopharma sector may have trended lower in early 2022, but activity could rebound into 2023 as the economic outlook becomes clearer.

United KingdomCorporate/Commercial Law

Dealmaking in the biopharma sector may have trended lower in early 2022, but activity could rebound into 2023 as the economic outlook becomes clearer.

Big pharma certainly seems to have returned to the table in the latter half of 2022, with notable acquisitions by Pfizer of Biohaven Pharmaceuticals and Global Blood Therapeutics and Amgen's acquisition of ChemoCentryx and recently announced deal to buy Horizon Therapeutics for $27.8 billion.

Even J.P. Morgan is aiming for success in the sector. The bank launched its new life science private equity arm in November with an eye on gene therapy and autoimmune fields, among others within the sector1.

Yet, M&A activity in the biopharma sector has not returned to 2021 levels, which was a record year across all industries. For life science, which includes biopharma, medtech and pharma services, the sector experienced healthy activity in 2021 with 145 deals valued at $40 billion, according to Bain & Company's 2022

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from